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EDITORIALS
PREDICTING AND DECIDING ON REMISSION IN RHEUMATOID ARTHRITIS
INFLAMMATION in rheumatoid arthritis (RA) seems
greatest at the onset of disease with the number of
swollen joints maximal at this time and a high
probability of developing joint damage or erosions
within 2 yr of the onset of disease [1-3]. Early
aggressive treatment of RA may alter the disease
course [4-6]. Thus, initiation of disease-modifying
anti-rheumatic drug (DMARD) therapy should not be
delayed beyond 3 months [1,7].
However, the diagnosis of RA may be difficult in
early disease [8] and the prognosis varies within wide
limits: some cases have a tendency to spontaneous
(natural) remission, while others result in chronic
inflammation with destruction of joints, functional
disability, morbidity and mortality. Also, conventional
therapies have significant adverse side-effects. Ideally,
one could thus recognize patients with self-limiting
disease to avoid unnecessary exposure to drug
side-effects.
Many studies examined the course and outcome of
patients with established RA, and investigated the role
of variables measured at the patient's initial visit as
prognostic factors [9]. While several sociodemographic,
clinical and laboratory variables have been shown to be
associated with a poor outcome in terms of decreased
survival, development of physical and work disability,
and worse quality of life, their usefulness in clinical
decision-making has not been demonstrated.
The study by Harrison et al. [10] on predicting
remission in this issue of the British Journal of
Rheumatology is unique, because it is based on a true
inception cohort of patients with inflammatory
polyarthritis in the community and because it examines
the usefulness of information currently available in
clinical practice. In a methodologically sound approach
using a prediction and validation set, Harrison et al.
could confinn the known association of male gender
and fewer than six tender joints at baseline with
remission. However, it was not possible to construct a
prediction rule of enough certainty to be useful in
clinical decision-making. It remains to be shown
whether additional information gained from immuno-
genetic markers allows a prediction rule useful for the
clinician to be derived.
The importance of predicting remission is dependent
on the rate of remission. The more frequent remission
occurs, the more often we may unnecessarily treat a
patient. To identify the risk of unnecessary treatment,
we would need to know the rate of 'spontaneous
remission' occurring without second-line or steroid
treatment. For ethical reasons, this cannot be studied
empirically, and because of confounding by treatment
and selection bias (treated patients are likely to have
more severe and progressive disease), spontaneous
remission cannot be studied epidemiologically. Closest
to the concept of 'spontaneous remission' comes
'natural remission' which Harrison et al. [10] studied
and defined as 'no arthritis on examination in a patient
who has not taken second-line drugs or steroids in the
preceding 3 months'. It is important to note that
remission in this population may not only occur
spontaneously, but may be induced by second-line
drugs.
The rates of 'natural remission' found by Harrison
et al. [10] are telling. Although the study was
community based, which was reflected by the relatively
low prevalence of rheumatoid factor positivity
indicating less severe disease, the rate of remission in
patients with inflammatory polyarthritis after 2 yr was
only 25%. Furthermore, only 9% of all patients were
in 'sustained remission' both at 1 and 2 yr. If remission
had been defined as 'no arthritis' on examination,
including treated patients would have given more
patients in remission. These data demonstrate that
while 'natural remission' (truly spontaneous or induced
with a sustained effect over 3 months) is rare, remission
can be achieved in a subset of patients treated with
second-line drugs at some point in the course of the
disease. The rates of remission in treated patients found
in a study by Prevoo et al. [11] in this issue of the
journal are similar. While 25% of patients fulfilled at
least once the criteria for remission during the study
period only 15% fulfilled the criteria at two consecutive
visits. In exemplary case studies, Prevoo et al. [11] show
that visits in which patients are in remission are not
always consecutive. Remission may thus be best
understood as an, often temporary, state at the lower
end on the continuum of systemic inflammation or
disease activity.
Although 'disease activity' and 'damage' have long
been used in rheumatology, only recently have these
concepts been operationalized and studied empirically
[12—14]. The Nijmegen group clearly showed that what
physicians describe as disease activity and use in their
decision-making regarding DMARD treatment can be
measured with few, weighted variables. With their
algorithm called the Disease Activity Score (DAS),
which integrates the number of swollen, tender joints
and sedimentation rate, disease activity can be
quantified. The DAS places disease activity on a
continuum from 0 to 10. The index is advantageous
because it provides a more reliable estimate than each
individual measure [12, 14]. The precision is ~0.6: a
change of >0.6 is unlikely to be by chance. For
patients with mild disease activity, a change of 0.6
represents a clinically relevant change. With more
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pronounced disease activity, a larger response of 1.2 is
required to be of clinical relevance.
The definition of remission in terms of the DAS
proposed by Prevoo et al. [11] is based on our current
understanding of systemic inflammation and its
consequences. Within this framework, control of
systemic inflammation reduces pain in the short term,
and damage and consequently disability in the long
term. In this understanding, disease activity and
damage are intermediate clinical outcomes, while pain
and disability are primary patient-orientated health
outcomes. The DAS is the target dimension which
needs to be adjusted as best as possible; and to define
remission in terms of the DAS one may contrast the
DAS against patient-orientated health-outcomes and
damage [15]. Depending on the selected external
standard, different cut-offs in terms of DAS are to be
expected.
Avoidance of damage and disability are the final
arbiters of disease control. In an earlier paper, van
Gestel et al. [13] showed that in group analysis a DAS
<2.4 was associated with halted X-ray progression.
Improved, more sensitive methods to show change in
bone density as a first indicator of damage may allow
an improved definition of the cut-off required to
prevent joint destruction [7]. In the current paper,
Prevoo et al. [11] gauged the DAS with the ARA
criteria for remission [16], which include the same
variables as used in the DAS, but in addition include
pain, fatigue and morning stiffness which are primary
patient-orientated health outcomes. The cut-off for
remission in terms of the DAS was 1.6. Both cut-offs
are most useful guidelines in clinical practice. Our goal
must be to reduce permanently disease activity below
2.4 or even 1.6.
While remission cannot be predicted with clinical
information currently available and while complete
remission may not be achieved, we are challenged to
optimize management. The DAS is a valid, precise and
sensitive measure of disease activity; and the new
empirically derived decision rules on response and
remission are invaluable for the rheumatologist to best
possibly control for disease activity and to alleviate
pain, maintain function, and slow the rate of joint
damage.
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